Marksans Pharma Balans Gezondheid
Financiële gezondheid criteriumcontroles 6/6
Marksans Pharma has a total shareholder equity of ₹20.9B and total debt of ₹2.4B, which brings its debt-to-equity ratio to 11.7%. Its total assets and total liabilities are ₹26.8B and ₹6.0B respectively. Marksans Pharma's EBIT is ₹4.0B making its interest coverage ratio 32.2. It has cash and short-term investments of ₹7.0B.
Belangrijke informatie
11.7%
Verhouding schuld/eigen vermogen
₹2.44b
Schuld
| Rente dekkingsratio | 32.2x |
| Contant | ₹7.01b |
| Aandelen | ₹20.86b |
| Totaal verplichtingen | ₹5.95b |
| Totaal activa | ₹26.81b |
Recente financiële gezondheidsupdates
We Think Marksans Pharma (NSE:MARKSANS) Can Manage Its Debt With Ease
Dec 02
Marksans Pharma (NSE:MARKSANS) Seems To Use Debt Quite Sensibly
Jun 21Marksans Pharma (NSE:MARKSANS) Could Easily Take On More Debt
Jun 14Is Marksans Pharma (NSE:MARKSANS) A Risky Investment?
Feb 19These 4 Measures Indicate That Marksans Pharma (NSE:MARKSANS) Is Using Debt Safely
Nov 19Recent updates
Is Now The Time To Put Marksans Pharma (NSE:MARKSANS) On Your Watchlist?
Oct 24Optimistic Investors Push Marksans Pharma Limited (NSE:MARKSANS) Shares Up 45% But Growth Is Lacking
Sep 21Marksans Pharma Limited (NSE:MARKSANS) Stock Rockets 26% But Many Are Still Ignoring The Company
Jul 28Solid Earnings May Not Tell The Whole Story For Marksans Pharma (NSE:MARKSANS)
Jun 07Does Marksans Pharma (NSE:MARKSANS) Deserve A Spot On Your Watchlist?
May 31Sentiment Still Eluding Marksans Pharma Limited (NSE:MARKSANS)
Feb 16Here's Why Marksans Pharma (NSE:MARKSANS) Has Caught The Eye Of Investors
Jan 26We Think Marksans Pharma (NSE:MARKSANS) Can Manage Its Debt With Ease
Dec 02Marksans Pharma (NSE:MARKSANS) Seems To Use Debt Quite Sensibly
Jun 21Robust Earnings May Not Tell The Whole Story For Marksans Pharma (NSE:MARKSANS)
Nov 17This Is The Reason Why We Think Marksans Pharma Limited's (NSE:MARKSANS) CEO Deserves A Bump Up To Their Compensation
Sep 16Marksans Pharma (NSE:MARKSANS) Is Increasing Its Dividend To ₹0.25
Sep 01Marksans Pharma (NSE:MARKSANS) Could Easily Take On More Debt
Jun 14Is Now The Time To Put Marksans Pharma (NSE:MARKSANS) On Your Watchlist?
May 27Is Marksans Pharma (NSE:MARKSANS) A Risky Investment?
Feb 19Marksans Pharma Limited's (NSE:MARKSANS) Stock's On An Uptrend: Are Strong Financials Guiding The Market?
Feb 04Here's Why We Think Marksans Pharma (NSE:MARKSANS) Is Well Worth Watching
Jan 20Do Institutions Own Marksans Pharma Limited (NSE:MARKSANS) Shares?
Jan 05
Shareholders Are Thrilled That The Marksans Pharma (NSE:MARKSANS) Share Price Increased 250%
Dec 21What Can We Conclude About Marksans Pharma's (NSE:MARKSANS) CEO Pay?
Dec 06These 4 Measures Indicate That Marksans Pharma (NSE:MARKSANS) Is Using Debt Safely
Nov 19Analyse van de financiële positie
Kortlopende schulden: MARKSANS's short term assets (₹18.6B) exceed its short term liabilities (₹3.9B).
Langlopende schulden: MARKSANS's short term assets (₹18.6B) exceed its long term liabilities (₹2.1B).
Schuld/ eigen vermogen geschiedenis en analyse
Schuldniveau: MARKSANS has more cash than its total debt.
Schuld verminderen: MARKSANS's debt to equity ratio has reduced from 19.9% to 11.7% over the past 5 years.
Schuldendekking: MARKSANS's debt is well covered by operating cash flow (94.4%).
Rentedekking: MARKSANS's interest payments on its debt are well covered by EBIT (32.2x coverage).